Cargando…
Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
AIMS: Prior studies have not fully characterized the haemodynamic effects of the angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF–PH). The aim of the Treatment of PH With Angiotensin II Receptor...
Autores principales: | Codina, Pau, Domingo, Mar, Barceló, Elena, Gastelurrutia, Paloma, Casquete, Daniel, Vila, Joan, Abdul‐Jawad Altisent, Omar, Spitaleri, Giosafat, Cediel, Germán, Santiago‐Vacas, Evelyn, Zamora, Elisabet, Ruiz‐Cueto, María, Santesmases, Javier, de la Espriella, Rafael, Pascual‐Figal, Domingo A., Nuñez, Julio, Lupón, Josep, Bayes‐Genis, Antoni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288803/ https://www.ncbi.nlm.nih.gov/pubmed/35588235 http://dx.doi.org/10.1002/ehf2.13952 |
Ejemplares similares
-
Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021) -
Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal
por: Bayes-Genis, Antoni, et al.
Publicado: (2020) -
Gender-Related Differences in Heart Failure Biomarkers
por: Cediel, Germán, et al.
Publicado: (2021) -
Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021) -
Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators
por: Codina, Pau, et al.
Publicado: (2022)